Valneva SE (NASDAQ:VALN) Given Average Recommendation of “Hold” by Brokerages

Valneva SE (NASDAQ:VALN – Get Rating) has been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $36.00.

Separately, Zacks Investment Research upgraded shares of Valneva from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th.

NASDAQ VALN opened at $24.50 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. Valneva has a 1-year low of $19.45 and a 1-year high of $67.84. The company has a 50 day moving average of $31.23 and a 200-day moving average of $39.03.

Valneva (NASDAQ:VALN – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.38. The business had revenue of $24.51 million during the quarter, compared to analyst estimates of $22.51 million. Sell-side analysts expect that Valneva will post 0.67 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in shares of Valneva during the second quarter worth $259,000. Morgan Stanley acquired a new position in shares of Valneva during the third quarter worth $97,000. Alps Advisors Inc. acquired a new position in shares of Valneva during the fourth quarter worth $3,369,000. Finally, Jane Street Group LLC increased its holdings in shares of Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares in the last quarter. Institutional investors and hedge funds own 0.21% of the company’s stock.

About Valneva (Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Stories